ARMP vs CRSP
ARMP: Armata is a clinical-stage phage biotech using engineered bacteriophages as a targeted, microbiome-friendly alternative to antibiotics for drug-resistant bacterial infections. CRSP: CRISPR Therapeutics develops gene-editing medicines using CRISPR/Cas9 technology, with the first approved CRISPR therapy (CASGEVY) for sickle cell disease and beta thalassemia, plus a pipeline of in vivo and cell therapy programs.
Side-by-side fundamentals
| Metric | ARMP | CRSP | Edge |
|---|---|---|---|
| Price as of 2026-07-22 close | $5.24 | $47.24 | |
| Market cap as of 2026-07-23 | $194M | $4.6B | |
| PEG as of 2026-07-23 | -0.00 | -0.21 | CRSP lower |
| Net margin as of 2026-07-23 | -5432.8% | -13856.5% | ARMP higher |
| Operating margin as of 2026-07-23 | -715.6% | -15754.2% | ARMP higher |
| ROE as of 2026-07-23 | -120.0% | -30.9% | CRSP higher |
| ROA as of 2026-07-23 | -356.6% | -24.5% | CRSP higher |
| Debt / equity as of 2026-07-23 | 1.38 | 0.32 | CRSP lower |
| Revenue growth (YoY) as of 2026-07-23 | +10.7% | -89.1% | ARMP higher |
| Revenue CAGR (3y) SEC XBRL | n/a | +43.1% | |
| Beta as of 2026-07-23 | 1.36 | 1.77 | |
| 1-year return as of 2026-07-22 close | +123.0% | -26.3% | ARMP higher |
Fundamentals: Finnhub, as of 2026-07-23. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-22.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.